|Bid||41.660 x 900|
|Ask||42.450 x 1100|
|Day's Range||41.10 - 41.97|
|52 Week Range||35.63 - 96.59|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.65|
Jeffrey Marrazzo, Spark Therapeutics CEO, joins 'Squawk Box' to discuss how his company is making breakthroughs in gene therapy and the fight to cure hemophilia.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced updated preliminary data on the first 12 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A. These data were presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego by Principal Investigator Lindsey A. George, M.D., assistant professor of pediatrics, The Perelman School of Medicine, University of Pennsylvania and attending physician in the Division of Hematology at Children’s Hospital of Philadelphia. The 12 participants in the Phase 1/2 trial received a single administration of investigational SPK-8011, including two at a dose of 5x1011 vector genomes (vg)/kg body weight, three at a dose of 1x1012 vg/kg and seven at a dose of 2x1012 vg/kg.
Bayer announced Thursday it will cut 12,000 jobs amid a strategic overhaul to focus on its pharmaceuticals, consumer health and crop science businesses.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Spark Therapeutics (ONCE) announces approval in Europe for its gene therapy, Luxturna, for treating inherited retinal dystrophy with RPE65 mutation. Novartis will develop and distribute it in Europe.
Spark's one-time gene therapy for a condition that leads to blindness if untreated will be marketed in Europe by Novartis under a licensing deal it signed in January.
Jeff Marrazzo has been the CEO of Spark Therapeutics Inc (NASDAQ:ONCE) since 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Spark Therapeutics will manufacture and supply LUXTURNA for Novartis, while Novartis has exclusive rights to pursue development, registration and commercialization in all other countries outside the U.S. PHILADELPHIA, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the European Commission has granted marketing authorization for LUXTURNA® (voretigene neparvovec), a one-time gene therapy for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Editas Medicine (EDIT) incurred general and administrative expenses of $13.33 million in the third quarter—compared to $12.63 million in the third quarter of 2017. The increase was due to higher stock-based compensation and employee-related expenses during this period.
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.” The mean rating for Editas Medicine stock is 2.4 with a target price of $47.29, which implies an upside potential of 75.8% over Editas Medicine’s closing price of $26.9 on November 14.
Editas Medicine (EDIT) is a leading genome editing company. The company’s product development strategy is to mainly target genetically defined diseases with a focus on debilitating illnesses.
Sangamo Therapeutics Inc. shares dropped as much as 10% in Wednesday premarket trade before evening out to a 4.6% decline after the company was downgraded to "neutral" at J.P. Morgan, with analyst Eric Joseph citing "growing skepticism about the company's lead development programs and their potential for value creation over the foreseeable future." Joseph also cut the company's price target by nearly 70% to $11. (Company shares closed at $10.80 on Tuesday.) Sangamo is a buzzy biotechnology company that focuses on a type of cutting-edge gene editing that utilizes "zinc finger" proteins. But whether the company's SB-525 program for hemophilia A is working "continues to elude, now with indefinite timelines," Joseph said, questioning whether the company can beat further-along competitors like BioMarin Pharmaceutical Inc. and Spark Therapeutics Inc. . The analyst also had questions about the company's SB-913 program, being developed for a metabolic disorder called Hunter syndrome; early results from a trial were recently released to skepticism, causing Sangamo shares to plummet. "We do believe that the breadth of the pipeline offers several potential catalysts longer term (12-18 months), but with management credibility increasingly coming into play, net-net, we view SGMO as a show-me story from here," Joseph said. Sangamo shares have dropped 32.1% over the last three months, compared with a 3.5% decline in the S&P 500 .
Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.
Spark Therapeutics (ONCE) delivered earnings and revenue surprises of -21.15% and -58.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Philadelphia-based company said it had a loss of $1.26 per share. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for ...
Children's Hospital of Philadelphia expects to double its viral vector manufacturing facility, to support cell and gene therapy, in its new space.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Nov. 6, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the third quarter that ended Sept. 30, 2018, and recent business highlights. To access a live audio webcast, please visit the “Investors” section of the Spark Therapeutics website at www.sparktx.com. A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 2370749, or by visiting the “Investors” section of the Spark Therapeutics website at www.sparktx.com.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced findings from three post-hoc analyses of data from the Phase 3 clinical trial of LUXTURNA® (voretigene neparvovec-rzyl) at the American Academy of Ophthalmology Annual Meeting in Chicago. LUXTURNA is a one-time gene therapy for the treatment of patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and viable retinal cells.